Justin B. Bartlett

TL;DR: The inhibitory effects of apremilast on pro‐inflammatory responses of human primary peripheral blood mononuclear cells, polymorphonuclear Cells, natural killer cells and epidermal keratinocytes were explored in vitro, and in a preclinical model of psoriasis.

TL;DR: This is the first report demonstrating in vivo T-cell costimulation by this class of compound, supporting a potential role for CC-4047 as an immunostimulatory adjuvant treatment.

TL;DR: It is shown that lenalidomide downregulated IRF4 levels in MM cell lines and bone marrow samples within 8 h of drug exposure, which indicates that this is an important mechanism by which lenalidOMide exerts its antitumour effects; and may provide a mechanistic biomarker to predict response to lenalidoide.

TL;DR: This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomides studies.

TL;DR: In this paper, methods of enhancing immune response to an immunogen in a subject are disclosed, and methods of reducing the sensitivity to an allergen to a subject. The methods comprise the administration of an immunomodulatory compound in specific dosing regimens that result in enhanced immune response or reduced sensitivity.